The Asia Pacific Newborn Screening Market
, by Products (Hearing Screening Devices, Mass Spectrometer, Pulse Oximetry, and Assay Kits and Reagents), by Test Type (Phenylketonuria (PKU), Critical Congenital Heart Defect (CCHD), Hearing Screening, Sickle Cell Disease, Maple Syrup Urine Disease (MSUD), Thyroid Disorder, Biotinidase Deficiency (BTD), and Others), by End User (Hospitals, Maternity & Specialty Clinics, and Diagnostic Centers), was valued at US$ 190.2 million
in 2018 and is projected to exhibit a CAGR of 12.7%,
during the forecast period (2018 - 2026), as highlighted in a new report published by .
Government bodies are focusing on initiatives to create awareness about newborn screening tests and are offering free screening services in some regions and rising funding. Furthermore, various government programs and legislations are also creating a conducive environment for growth of the Asia pacific newborn screening market.
For instance, a newborn screening program was recommended by the World Health Organization (WHO) to safeguard the health of children across the globe. Under this program, numerous policies and initiatives have taken by the Human Services Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC) and the U.S. Department of Health, advocacy groups such as the March of Dimes and Japan’s Society of Obstetrics and Gynecology (JSOG) and UK (PEACH). The World Health Organization (WHO) is focusing on allocation of necessary resources as an additional investment of US$ 0.20 cents per person, which can save 2 of every 3 newborns in low and middle income countries by 2030.
Browse 32 Market Data Tables and 40 Figures spread through 193 Pages and in-depth TOC on "Asia Pacific Newborn Screening Market, by Products (Hearing Screening Devices, Mass Spectrometer, Pulse Oximetry, and Assay Kits and Reagents), by Test Type (Phenylketonuria (PKU), Critical Congenital Heart Defect (CCHD), Hearing Screening, Sickle Cell Disease, Maple Syrup Urine Disease (MSUD), Thyroid Disorder, Biotinidase Deficiency (BTD), and Others), by End User (Hospitals, Maternity & Specialty Clinics, and Diagnostic Centers) - Forecast to 2026"
To know the latest trends and insights related to Asia Pacific newborn screening market, click the link below:
Development of cost-effective newborn screening devices is a challenging aspect in emerging countries. Manufacturers could focus on emerging countries such as China, India, Brazil, and South Africa for development of newborn screening devices, owing to relatively high birth rates.
Furthermore, manufacturers could focus on developing novel newborn screening methodology, which will be affordable, as the healthcare infrastructure is rapidly enhancing in Asia pacific countries and the regulatory scenario is also favorable for growth of the market.
In November 2018, GE Healthcare collaborated with Beyond Zero Initiative to improve access to quality and affordable primary healthcare services in Kisumu County.
Key Takeaways of the Asia Pacific Newborn Screening Market:
- The Asia Pacific newborn screening market is expected to expand at a CAGR of 12.7% during the forecast period (2018 – 2026), owing to increasing government support to deploy efficient and cost-effective newborn screening devices
- Among product type, assay kits and reagents segment is expected to witness maximum growth, owing to engagement of key players in offering superior quality reagents to screen disorders and deficiencies in newborn
- Various national governments in the region are actively promoting the newborn hearing tests, which is expected to fuel demand for hearing screening in the near future. For instance, according to the International Journal of Preventative Health 2015 report, the Department of Prevention of Communication Disorders of All India Institute of Speech and Hearing (AIISH) located in the Southern India conducts infant screening for hearing disorder on regular basis in different hospitals using Behavioral Observational Audiometry, Otoacoustic Emissions (OAE) screening, and administering High Risk Register (HRR).
- Major players operating in the Asia Pacific newborn screening market include Medtronic plc, Agilent Technologies, Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC, GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc., Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.